EGFR and cancer: Diarrhea, a common side effect of many cancer treatments, including chemotherapeutic agents, targeted therapies, and pelvic radiotherapy, is one of the most common adverse events reported during treatment with a TKI, and can be dose-limiting for TKIs that block EGFR signaling [41].